Inhibition of PAI-1: A New Anti-thrombotic Approach
Current Drug Target -Cardiovascular & Hematological Disorders · 2002
DOI: 10.2174/1568006023337727 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Drug Target -Cardiovascular & Hematological Disorders, 2002. Verfasst von Qingyu Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Cardiovascular Research and Medicinal Chemistry, Berlex Biosciences, 15049 San Pablo Avenue, Richmond, CA 94804, USA. qingyu_wu@berlex…. Die Arbeit wurde bisher 31-mal zitiert (Crossref).
Abstract (Originalsprache)
Proteolytic degradation of fibrin (fibrinolysis) is mediated by plasminogen and its activators, tissue-type plasminogen activator (tPA(1)) and urokinase (uPA). Fibrinolysis is critical for preventing thrombus growth and restoring blood flow following thrombotic vascular occlusion. Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily, is the principal inhibitor of tPA and uPA in the fibrinolytic system. High levels of circulating PAI-1 are associated with a number of thrombotic diseases. In animal studies, transgenic mice overexpressing human PAI-1 develop spontaneous thrombosis, whereas PAI-1-deficient mice are more resistant to venous or arterial thrombosis. Furthermore, inhibition of PAI-1 activity prevents thrombus formation in animal models. The antithrombotic effects of PAI-1 inhibition are achieved by enhancing endogenous fibrinolytic activity without directly affecting blood coagulation and platelet function. Phenotypic analysis of PAI-1 deficiency in both human and mouse suggests that inhibition of PAI-1 will not lead to severe bleeding or other major adverse effects. Thus, PAI-1 inhibitors represent a new class of antithrombotic drugs with a possible wider therapeutic index than conventional antiplatelet and anticoagulant agents. This review summarizes the role of PAI-1 in thrombotic diseases and recent progress in the development of small molecule PAI-1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Cardiovascular Research and Medicinal Chemistry, Berlex Biosciences, 15049 San Pablo Avenue, Richmond, CA 94804, USA. qingyu_wu@berlex.com
Zitieren
APA
Wu, Q., & Zhao, Z. (2002). Inhibition of PAI-1: A New Anti-thrombotic Approach. Current Drug Target -Cardiovascular & Hematological Disorders. https://doi.org/10.2174/1568006023337727
Vancouver
Wu Q, Zhao Z. Inhibition of PAI-1: A New Anti-thrombotic Approach. Current Drug Target -Cardiovascular & Hematological Disorders. 2002. doi:10.2174/1568006023337727
BibTeX
@article{Wu2002,
author = {Wu, Qingyu and Zhao, Zuchun},
title = {Inhibition of PAI-1: A New Anti-thrombotic Approach},
journal = {Current Drug Target -Cardiovascular & Hematological Disorders},
year = {2002},
doi = {10.2174/1568006023337727}
}
EUVIMED